The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | MYLOX-1: Phase IIa study of GB2064, an oral LOXL-2 inhibitor in myelofibrosis
Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares her excitement for the recently launched MYLOX-1 study (NCT04679870) which is looking at the impact of LOXL-2 inhibition in patients with myelofibrosis (MF). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Transcript
The MYLOX-1 study was presented as a trials-in-progress poster at the EHA meeting 2022. It’s a super exciting study, but there’s no results to date. The study will be fully accrued shortly and it’ll be really interesting as a kind of first-in-class, looking at LOXL inhibition and its ability to alter the bone marrow microenvironment and improve hematopoiesis for patients with myelofibrosis...
The MYLOX-1 study was presented as a trials-in-progress poster at the EHA meeting 2022. It’s a super exciting study, but there’s no results to date. The study will be fully accrued shortly and it’ll be really interesting as a kind of first-in-class, looking at LOXL inhibition and its ability to alter the bone marrow microenvironment and improve hematopoiesis for patients with myelofibrosis. For me, it’s really exciting because it reflects a novel mode of therapy, probably not very toxic, likely to be well tolerated and therefore easy to put in a combination. So I was super excited to see that data and will be looking for results as they become available.
Read more...
Disclosures
Research funding: Celgene, Constellation, Novartis
Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
